434 completed, 33 recruiting, 16 unknown, 13 active not recruiting. 518 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 518 | Completed 434, Recruiting 33, Unknown 16, Active not recruiting 13, Not yet recruiting 9, Terminated 8, Withdrawn 4, Suspended 1 |
| Phase 2 | 4 | Active not recruiting 2, Completed 2 |
Follow Healthy Volunteer: new trials by email Literature Review of Healthy Volunteer trials Research Report on Healthy Volunteer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Sirolimus on Asymptomatic ApoE4 Carriers Sirolimus (rapamycin), Placebo - Genetic Predisposition to Disease, Healthy Volunteer | Phase 1 | Recruiting | University of Missouri-Columbia | 225 | 2026-12-01 | 2026-10-05 |
| Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers TRL1068, a human monoclonal antibody - Healthy Volunteer | Phase 1 | Not yet recruiting | Trellis Bioscience LLC | 14 | 2026-10-01 | 2026-06-12 |
| An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 Inhibition Rilzabrutinib, Rosuvastatin, Digoxin - Healthy Volunteer | Phase 1 | Active not recruiting | Sanofi | 14 | 2026-10-01 | 2026-10-21 |
| A Study to Learn How ASP3082 is Processed in Healthy Men 14C-labeled ASP3082 - Healthy Volunteer | Phase 1 | Completed | Astellas Pharma Global Development, Inc. | 8 | 2026-08-28 | 2026-11-03 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of Viaca (Sildenafil + Cabergoline) Compared With Sildenafil and Cabergoline Viaca, Sildenafil 50 mg, Cabergoline 0.5 MG - Erectile Dysfunctions, Healthy Volunteer | Phase 1 | Not yet recruiting | Yanping Kong | 30 | 2026-08-01 | 2026-07-28 |
| A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants ABBV-859, Placebo for ABBV-859 - Healthy Volunteer | Phase 1 | Recruiting | AbbVie | 64 | 2026-07-28 | 2026-08-03 |
| A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo BIIB144, Placebo - Healthy Volunteer | Phase 1 | Recruiting | Biogen | 48 | 2026-07-21 | 2026-07-27 |
| A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants MT-201 - Healthy Volunteer | Phase 1 | Recruiting | Mirador Therapeutics, Inc. | 25 | 2026-07-16 | 2026-08-21 |
| Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants Ubrogepant - Healthy Volunteer | Phase 1 | Active not recruiting | AbbVie | 52 | 2026-07-14 | 2026-10-13 |
| A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants Nacresertib, Itraconazole - Healthy Volunteer | Phase 1 | Active not recruiting | AbbVie | 12 | 2026-06-23 | 2026-09-18 |
| A Study Testing the Safety and Effects of FB102 in Healthy Volunteers FB102 Single dose - Part A, FB102 Multiple doses - Part B, FB102 Placebo - Healthy Volunteer | Phase 1 | Recruiting | Forte Biosciences, Inc. | 64 | 2026-06-23 | 2026-10-21 |
| A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syringe in Healthy Adult Participants Efgartigimod PH20 SC via PFS, Efgartigimod PH20 SC via AI - Healthy Volunteer, Healthy Adult Participants | Phase 1 | Completed | argenx | 32 | 2026-06-19 | 2026-10-14 |
| First-in-human Study of HSK56630 in Healthy Subjects HSK56630, Placebo - Healthy Volunteer | Phase 1 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 40 | 2026-06-17 | 2026-06-24 |
| A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants Adimanebart IV, Adimanebart SC - formulation A, Adimanebart SC - formulation B - Healthy Volunteers (HV), Healthy Volunteer | Phase 1 | Recruiting | argenx | 52 | 2026-06-12 | 2026-06-29 |
| A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults REGN22044, Placebo - Healthy Volunteer | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 88 | 2026-06-05 | 2026-08-25 |
| A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants Risankizumab - Healthy Volunteer | Phase 1 | Recruiting | AbbVie | 60 | 2026-06-04 | 2026-07-01 |
| Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women Standard dose rifampicin, High dose rifampicin, Standard dose isoniazid - Tuberculosis Infection, Healthy Volunteer | Phase 1 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 60 | 2026-06-01 | 2026-11-02 |
| A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants Bretisilocin - Healthy Volunteer | Phase 1 | Completed | AbbVie | 26 | 2026-05-26 | 2026-09-30 |
| First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis REGN20423, Placebo - Healthy Volunteer, Atopic Dermatitis | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 144 | 2026-05-22 | 2026-10-07 |
| Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions Vancomycin (IV) - Healthy Volunteer, Hypersensitivity Reactions | Phase 1 / Phase 2 | Active not recruiting | Johns Hopkins University | 25 | 2026-05-21 | 2026-10-27 |
Showing 20 of 518. Sign in to see all of them.
Renal Insufficiency (4) · Dermatitis, Atopic (3) · Cardiovascular Diseases (2) · Diabetes Mellitus, Type 2 (2) · Heart Failure (2) · Hidradenitis Suppurativa (2) · Influenza, Human (2) · Neoplasms (2) · Urinary Bladder, Overactive (2) · Urinary Incontinence (2) · Adenoviridae Infections (1) · Alzheimer Disease (1) · Amyotrophic Lateral Sclerosis (1) · Behavioral Symptoms (1) · Breast Feeding (1)
Infections (12) · Nervous System Diseases (10) · Pathological Conditions, Signs and Symptoms (9) · Urogenital Diseases (9) · Male Urogenital Diseases (8) · Central Nervous System Diseases (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Mental Disorders (7) · Urologic Diseases (7) · Genetic Diseases, Inborn (6) · Immune System Diseases (6) · RNA Virus Infections (6) · Respiratory Tract Diseases (6)
Ritonavir (21) · Itraconazole (17) · danoprevir (15) · Moxifloxacin (13) · Midazolam (12) · Rifampin (8) · 2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine (7) · Rabeprazole (7) · aleglitazar (7) · Digoxin (5) · Ketoconazole (5) · Metformin (5) · Rosuvastatin Calcium (5) · dolutegravir (5) · 4-amino-8-(2-fluoro-6-methoxy-phenyl)-N-propylcinnoline-3-carboxamide (4)
Hoffmann-La Roche (109) · AbbVie (38) · Genentech, Inc. (34) · Biogen (25) · AstraZeneca (20) · Celgene (12) · International Bio service (12) · Pfizer (11) · Regeneron Pharmaceuticals (9) · GlaxoSmithKline (7) · Astellas Pharma Inc (6) · Amgen (5) · Yuhan Corporation (5) · Genzyme, a Sanofi Company (4) · Immunome, Inc. (4)
United States (265) · United Kingdom (41) · China (31) · Netherlands (29) · France (26) · Australia (18) · Canada (18) · Japan (18) · South Korea (14) · Germany (12) · Belgium (11) · New Zealand (10) · Poland (4) · Singapore (4) · Russia (3)
Leon Carayannopoulos, MD (4) · Porranee Puranajoti, Ph. D (3) · Scott Holden, M.D. (3)
PMID 27381392, PMID 30091852, PMID 37563858, PMID 37705327, PMID 41058119, PMID 42133202, PMID 18190252, PMID 19419343, PMID 22500821, PMID 22980315, PMID 23712757, PMID 24057039, PMID 24627419, PMID 24998012, PMID 25289522, PMID 25724156, PMID 26055360, PMID 26312582, PMID 26363899, PMID 26691837, PMID 27154174, PMID 27368672, PMID 28559255, PMID 28769925, PMID 29178442, PMID 29909549, PMID 30305980, PMID 30910894, PMID 30957581, PMID 31043095, PMID 31303281, PMID 31604104, PMID 31883703, PMID 32105576, PMID 32274653, PMID 32337660, PMID 32851809, PMID 32857315, PMID 33325799, PMID 33488576, PMID 33529172, PMID 33778928, PMID 33813736, PMID 34145168, PMID 34176392, PMID 35460392, PMID 35501309, PMID 35644931, PMID 35691544, PMID 35982464
2014 (11), 2017 (7), 2015 (6), 2018 (4), 2019 (3), 2025 (2), 2008 (1), 2009 (1), 2016 (1), 2023 (1), DP1DA060602 (1), R21AI182531 (1), UG3AG094957 (1), UG3DA050308 (1)